Business Wire

IDEMIA Launches its Global Fintech Accelerator Card Program to Support FinTechs and Neobanks in Their Card Issuance Process

5.10.2020 12:03:00 EEST | Business Wire | Press release

Share

In the context of a rapid transformation of the banking industry, IDEMIA, the global leader in Augmented Identity, supports FinTechs and neobanks with the launch of the Global Fintech Accelerator Card Program. This new program allows a rapid process from cardholder onboarding - to card issuance.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005366/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

IDEMIA’s leadership in card manufacturing, as the number 1 global FinTech card issuance partner, is based on a solid experience of a global dedicated FinTech team and a network of 30 Service Centers in 26 countries around the world. FinTechs can leverage the capability and know-how of IDEMIA to enable card issuance into the marketplace anywhere in the world.

Over the years, IDEMIA has built the largest world wide network of personalization centers designed to optimize responsiveness and proximity to the cardholder for fast delivery times. All of the 30 Service Centers are supported by a Common Personalization System (CPS) that allows card profile developments to be instantly and securely transferred and re-used in any one of them, helping globally aspiring Fintechs to expand rapidly. In addition to CPS, all IDEMIA sites are inter-connected via the IDEMIA Hub with a connection to almost all local and global card processors and BaaS providers so that services and solutions can be safely replicated, extended, shared and optimized across the world.

The IDEMIA FinTech Accelerator CardProgram benefits from dedicated local, regional and global FinTech teams that are trained to help to create a card product that will ensure FInTechs can fully differentiate their product in the marketplace. Before manufacturing the cards, the needs of various stakeholders within the FinTech’s organization are taken into consideration to guarantee an optimal start of the card issuing journey. IDEMIA provides advice on how to use innovative solutions to help FinTechs to further differentiate such as card packaging solutions, IDEMIA metal cards, biometric cards (F.CODE), cards with a dynamic security code (MOTION CODE) and recycled cards (GREENPAY).

With IDEMIA’s digital assets, customers will be able to blend the physical card with digital services. The FinTech Accelerator Card Program not only provides a seamless process for a successful card launch, but also it delivers additional digital services such as mobile identity proofing for customer on-boarding and IDEMIA Card Connect, a way to activate a card or provide secure customer authentication by tapping the contactless card on the phone. IDEMIA’s digital assets can also enable FinTechs to enrich their mobile banking apps with new payment features via digital cards, reinventing the customer journey for both proximity and remote payments.

“We recognize that the FinTech world needs innovative solutions and to move quickly. Our Accelerator Card Program does just that and ensures that we can help the processors, BaaS providers and FinTech customers get their products to market as quickly as possible and expand globally without the need to start a new project in each country”
Stuart Yaxley | Senior Vice President Global Accounts and FinTechs for Financial Institutions at IDEMIA

“IDEMIA’s FinTech accelerator card program and Hub have been strategic levers in creating an advanced interface and facilitating business for all of our existing and future global fintech customers, including providing a wide variety of valuable solutions such as metal cards, recycled plastic cards and digital solutions. The IDEMIA FinTech team are extremely knowledgeable in their field, and with our combined global reach, our partnership is a powerful force as we support our customer’s international growth journeys. Moreover, their global service delivery team have made sure that the interface that we have set up with them is designed to work with all of the needs and expectations of our customers.”
Neil Harris | Group Chief Commercial Officer of GPS - Global Processing Services.

“We at OneCard have set out to reimagine Credit Cards and have launched a Mobile First Metal Credit Card. We needed a partner who has the same philosophy and outlook of innovation and consumer first. The IDEMIA FinTech team was our partner of choice to create the stunning 16 g Metal OneCard. Their personalized Metal Card offering has helped differentiate OneCard. IDEMIA has been able to deliver the product for us in these challenging times also. ”
Vibhav Hathi, Cofounder & CMO, OneCard

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press:
Hanna Sebbah
idemia@havas.com
+33 (0) 6 63 73 30 30

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 05:00:00 EEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 02:51:00 EEST | Press release

Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equity among HCPs, patients, regulators and other stakeholders. A global leader in women’s health, the company’s portfolio includes more than 70 products across Women’s Health and General Medicines, which includes biosimila

PMC Organometallix Announces Price Increase on All Products25.4.2026 00:02:00 EEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi ® arbitral award in favor of AOP Health24.4.2026 19:52:00 EEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 17:37:00 EEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be entitled to benefits including enhanced communications and a shortened 1-2 month review time following filing of a New Drug Application (NDA), while maintaining FDA’s rigorous safety and efficacy standards. “We are honored and grateful to be selected for the CNPV which is a clear validation of both the urgent unmet need facing millions of people living with treatment resistant depression and the innovative science of COMP360,” said Kabir Nath, Chief Executive Officer of Compass Pathways. “As the most advan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye